Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPC for Tilt Induced Syncope
NCT04972123Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jul 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of capsaicin, phenylephrine and caffeine in vasovagal syncope (2 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG and Time to Syncope or Near-syncope After CPC or Placebo Administration. Started Jul 2021; status: completed.
02
Drugs
capsaicinphenylephrinecaffeine
03
Conditions
vasovagal syncope
Beyond the preview
Go deeper on NCT04972123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972123.